Abstract
The identification of viral and host factors involved in hepatitis C virus (HCV) replication was a key prerequisite for the discovery and further exploration of antiviral drug targets. As of today, numerous direct-acting antiviral agents (DAAs), as well as host-targeting agents (HTAs), have been developed and entered clinical testing. The goal to omit pegylated interferon due to its unfavorable side-effect profile from novel HCV therapeutic approaches led to an expedited design and competitive conduct of DAA combination trials striving for easily applicable, all-oral HCV treatments. Approval of several interferon-free regimens is awaited in the near future (2014/2015). Results of different DAA combination trials (without nucleos(t)ide polymerase inhibitors) and trials involving HTAs are reviewed herein.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
MeSH terms
-
Animals
-
Antiviral Agents / therapeutic use*
-
Carrier Proteins / antagonists & inhibitors
-
Carrier Proteins / metabolism
-
Drug Design
-
Drug Resistance, Viral
-
Drug Therapy, Combination
-
Hepacivirus / drug effects*
-
Hepacivirus / enzymology
-
Hepacivirus / genetics
-
Hepacivirus / growth & development
-
Hepatitis C / diagnosis
-
Hepatitis C / drug therapy*
-
Hepatitis C / virology
-
Humans
-
Interferons / therapeutic use
-
Intracellular Signaling Peptides and Proteins
-
Molecular Targeted Therapy
-
Nucleosides / therapeutic use
-
Nucleotides / therapeutic use
-
Protease Inhibitors / therapeutic use
-
Treatment Outcome
-
Viral Nonstructural Proteins / antagonists & inhibitors
-
Viral Nonstructural Proteins / metabolism
Substances
-
Antiviral Agents
-
Carrier Proteins
-
Intracellular Signaling Peptides and Proteins
-
NS3 protein, hepatitis C virus
-
NS4A cofactor peptide, Hepatitis C virus
-
Nucleosides
-
Nucleotides
-
Protease Inhibitors
-
Viral Nonstructural Proteins
-
Interferons